Intellectual Property India Publishes Patent Application for Indazole Derivatives Useful As Inhibitors Of Nod-Like Receptor Protein 3

MUMBAI, India, Aug. 17 -- Intellectual Property India has published a patent application (202617084438 A) filed by Merck Sharp & Dohme LLC on July 09, 2026, for Indazole Derivatives Useful As Inhibitors Of Nod-Like Receptor Protein 3.

Inventors include Brill, Zachary G.; Hayes, Donna A. A. W.; Lam, Tom M.; Mcclymont, Kyle S. Number; Matsuura, Bryan S.; Merchant, Rohan Rajiv; Nair, Anilkumar G.; and Qi, Ning.

The application for the patent was published on August 14, 2026, under issue no. 33/2026.

Abstract: Novel compounds of Formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control, and suppression of diseases mediated by NLPR3. The compounds of the present invention may be useful in the treatment, prevention or management of diseases, disorders and conditions mediated by NLRP3 such as, but not limited to, obesity, gout, pseudogout, CAPS, NASH, MASH, fibrosis, osteoarthritis, atherosclerosis, heart failure, idiopathic pericarditis, myocarditis, atopic dermatitis, hidradenitis suppurativa, inflammatory bowel disease, cancer, Alzheimer's Disease, Parkinson's Disease, dementia with Lewy bodies (DLB), and traumatic brain injury.

Disclaimer: Curated by HT Syndication.